Überprüfung…
Automatisch übersetzt. Dosierung und Warnhinweise: bitte im englischen Original prüfen. Auf Englisch lesen
Homepage / Eingetragen in Nigeria / Flut-250 Tablets

Flut-250 Tablets

NAFDAC Reg.-Nr. A4-7974 Medikament

Registriert bei NAFDAC. Registrierung aktivAs of 29 October 2026 · synced automatically from official sources.
Produkt-
Flut-250 Tablets
NAFDAC-Nummer
A4-7974
Wirkstoff
Flutamide
Stärke
250 mg
Form
Tablet
Hersteller
Not listed
Applicant (holder)
Dony-Triumph and Company Nigeria Limited
Approved
24 Jun 2021
Status
Inactive View on NAFDAC ↗
Registration valid to
23 Jun 2026
WER WARNT
None found
Community reports
None
Times checked
0

About the medicine: Flutamide: uses, dosage and brands worldwide

What we found

  • Flut-250 Tablets is on the NAFDAC register with an active registration (A4-7974). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Flut-250 Tablets

What the official label says. If a doctor prescribed it, follow the prescription. Your pack's leaflet comes first if it is different.

Serious warning: Hepatic Injury There have been postmarketing reports of hospitalization and rarely death due to liver failure in patients taking Eulexin ® . Evidence of hepatic injury included elevated serum transaminase levels, jaundice, hepatic encephalopathy and death related to acute hepatic failure. The hepatic injury was reversible after discontinuation of therapy in some patients. Approximately half of the reported cases occurred within the initial 3 months of treatment with Eulexin ® . …
Who it is for

Eulexin ® capsules are indicated for use in combination with LHRH-agonists for the management of locally confined Stage B 2 -C and Stage D 2 metastatic carcinoma of the prostate. Stage B 2 -C Prostatic Carcinoma Treatment with Eulexin ® capsules and the goserelin acetate implant should start eight weeks prior to initiating radiation therapy and continue during radiation therapy. Stage D 2 Metastatic Carcinoma To achieve benefit from treatment, Eulexin ® capsules should be initiated with the LHRH-agonist and continued until progression.

How to take it and how often

The recommended dosage is 2 capsules 3 times a day at 8 hour intervals for a total daily dose of 750 mg.

While you are taking it

Patients should be informed that Eulexin ® capsules and the drug used for medical castration should be administered concomitantly, and that they should not interrupt their dosing or stop taking these medications without consulting their physician.

Talk to a doctor first if
  • Eulexin ® capsules are contraindicated in patients who are hypersensitive to Eulexin ® or any component of this preparation
  • Eulexin ® capsules are contraindicated in patients with severe hepatic impairment (baseline hepatic enzymes should be evaluated prior to treatment)
Medicines it may not mix with

Increases in prothrombin time have been noted in patients receiving long-term warfarin therapy after Eulexin ® was initiated. Therefore close monitoring of prothrombin time is recommended and adjustment of the anticoagulant dose may be necessary when Eulexin ® capsules are administered concomitantly with warfarin.

Warnings

Hepatic Injury SEE BOXED WARNINGS Use in Women Eulexin ® capsules are for use only in men. This product has no indication for women and should not be used in this population, particularly for nonserious or nonlife-threatening conditions. Fetal toxicity Eulexin ® may cause fetal harm when administered to a pregnant woman (see Pregnancy ). Aniline toxicity One metabolite of Eulexin ® is 4-nitro-3-fluoro-methylaniline. Several toxicities consistent with aniline exposure, including methemoglobinemia, hemolytic anemia and cholestatic jaundice have been observed in both animals and humans after Eulexin ® administration. In patients susceptible to aniline toxicity (e.g. …

Possible side effects

Stage B 2 -C Prostatic Carcinoma Treatment with Eulexin ® capsules and the goserelin acetate implant did not add substantially to the toxicity of radiation treatment alone. The following adverse experiences were reported during a multicenter clinical trial comparing Eulexin ® + goserelin acetate implant + radiation versus radiation alone. The most frequently reported (greater than 5%) adverse experiences are listed below: Adverse Events During Acute Radiation Therapy (within first 90 days of radiation therapy) (n=231) Goserelin Acetate Implant + Eulexin ® + Radiation (n=235) Radiation Only % All % All Rectum/Large Bowel 80 76 Bladder 58 60 Skin 37 37 Adverse Events During Late Radiation Phas …

Pregnancy and breastfeeding

Pregnancy Pregnancy Category D There was decreased 24 hour survival in the offspring of pregnant rats treated with Eulexin ® at doses of 30, 100 or 200 mg/kg/day (approximately 3, 9 and 19 times the human dose). A slight increase in minor variations in the development of the sternebrae and vertebrae was seen in fetuses of rats treated with two higher doses. Feminization of the male rats also occurred at the two higher dose levels. …

If you take too much

In animal studies with Eulexin ® alone, signs of overdose included hypoactivity, piloerection, slow respiration, ataxia, and/or lacrimation, anorexia, tranquilization, emesis, and methemoglobinemia. Clinical trials have been conducted with Eulexin ® in doses up to 1500 mg per day for periods up to 36 weeks with no serious adverse effects reported. Those adverse reactions reported included gynecomastia, breast tenderness, and some increases in SGOT. The single dose of Eulexin ® ordinarily associated with symptoms of overdose or considered to be life-threatening has not been established. …

How to store it

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

If you miss a dose

Take it when you remember, unless it is nearly time for the next dose. Then skip the missed one. Never take two doses at once to make up for it. Check your leaflet, as some medicines are different.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2025-02-04.

Label for flutamide, the active ingredient registered with NAFDAC.

Check your pack of Flut-250 Tablets

Add the expiry date on your pack for a full Trust Score.

Or take photos of the pack
3 free checks left today Official sources: U.S. FDA · EMA (EU) · NAFDAC · WHO alerts

About Flut-250 Tablets

What is in Flut-250 Tablets?

Flut-250 Tablets contains Flutamide (250 mg), as tablet, according to its NAFDAC registration record.

Is Flut-250 Tablets registered with NAFDAC?

Yes. Flut-250 Tablets is listed on the NAFDAC register under registration number A4-7974, and its registration is active as of 29 October 2026.

Has Flut-250 Tablets been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Flut-250 Tablets in our automatically synced alert list.

How can I check that my pack of Flut-250 Tablets is genuine?

Run a free authenticity scan with the NAFDAC number A4-7974, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Flut-250 Tablets?

Follow your prescription or the leaflet in your pack. The official label says: The recommended dosage is 2 capsules 3 times a day at 8 hour intervals for a total daily dose of 750 mg.…

What is Flut-250 Tablets used for?

Eulexin ® capsules are indicated for use in combination with LHRH-agonists for the management of locally confined Stage B 2 -C and Stage D 2 metastatic carcinoma of the prostate. Stage B 2 -C Prostatic Carcinoma Treatment with Eulexin ® capsules and the goserelin acetate implant should start eight weeks prior to initiating radiation therapy and continue during radiation therapy. Stage D 2 Metastat (Summarised from the official U.S. FDA label for flutamide. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Flut-250 Tablets? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.